S-1/A: Entero Therapeutics Seeks $6M Capital Raise to Fund Adrulipase Development Amidst Financial Strain and Strategic Divestiture

Entero Therapeutics, Inc. is offering 15.2 million shares and pre-funded warrants to raise approximately $4 million, aiming to fund its lead drug candidate Adrulipase and address significant financial challenges, including a planned rescission of its ImmunogenX merger.

Summary

• Entero Therapeutics is conducting a public offering of 15,228,426 shares of common stock or pre-funded warrants, aiming to raise approximately $4 million in net proceeds at an estimated price of $0.394 per share.
• The company plans to use the net proceeds primarily to advance its lead drug candidate, Adrulipase (approximately $1.4 million), allocate up to $1.5 million for marketing and advertising services, and repay approximately $1.1 million in outstanding liabilities, including up to $695,000 of ImmunogenX, LLC's accounts payable, assuming the rescission agreement closes.
• Entero Therapeutics is in the process of rescinding its March 2024 merger with ImmunogenX, Inc. (IMGX), a move intended to eliminate secured debt obligations, streamline operations, and focus resources on its core Adrulipase program.
• The rescission agreement, expected to close on or prior to June 30, 2025, subject to shareholder approval, will transfer ImmunogenX, LLC's membership interests back to its former shareholders, with ImmunogenX, LLC remaining responsible for approximately $2,436,338 of its secured debt.
• The company reported cash and cash equivalents of approximately $66,000 as of March 31, 2025, and an accumulated deficit of approximately $203.6 million.
• Entero Therapeutics incurred net losses of approximately $18.1 million in 2024 and $15.8 million in 2023, and its independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company has significantly reduced its full-time employee headcount from 15 as of March 31, 2024, to two (2) as of May 28, 2025, due to severe capital constraints.
• The Adrulipase Phase 2b monotherapy trial did not meet its primary efficacy endpoint, with mean Coefficient of Fat Absorption (CFA) of 66% at the 2240 mg/day dose and 53% at the 4480 mg/day dose, falling short of the targeted 80%.

Sentiment

Score: 3

Explanation: The company is in a precarious financial position with significant accumulated losses, minimal cash on hand, and a going concern qualification. While the strategic refocus on Adrulipase and the rescission of the ImmunogenX merger are positive strategic moves to reduce liabilities and streamline operations, the failure of the Adrulipase monotherapy trial to meet its primary endpoint and ongoing Nasdaq compliance issues present substantial challenges and risks. The need for immediate and future capital raises, coupled with drastic employee reductions, indicates severe operational distress. The positive combination therapy results for Adrulipase offer a glimmer of hope, but overall, the outlook remains highly uncertain and risky.

Positives

• Strategic refocus on Adrulipase, identified as the company's most valuable asset, by divesting non-core assets like Latiglutenase and Capeserod.
• The planned rescission of the ImmunogenX merger is expected to eliminate approximately $2.44 million in secured debt obligations and reduce contingent liabilities, significantly improving the balance sheet if successful.
• Positive Phase 2 data for Adrulipase in combination therapy with PERT showed clinically meaningful improvements in Coefficient of Fat Absorption (CFA) to over 80% and positive impacts on weight gain and other secondary endpoints in CF patients.
• Adrulipase addresses a substantial market opportunity with over 40,000 CF patients and 300,000-500,000 chronic pancreatitis patients suffering from EPI in the U.S.
• The company secured a $2.0 million revolving loan agreement in January 2025 to provide critical liquidity.

Negatives

• Significant operating losses and negative cash flows since inception, with an accumulated deficit of approximately $203.6 million as of March 31, 2025.
• Cash and cash equivalents were critically low at approximately $66,000 as of March 31, 2025.
• Independent auditors have issued going concern qualifications for the financial years ended December 31, 2023, and 2024, indicating substantial doubt about the company's ability to continue operations.
• The company faces immediate and substantial dilution of $0.46 per share for new investors due to the offering price being significantly higher than the current net tangible book value per share.
• The Adrulipase Phase 2b monotherapy trial did not meet its primary efficacy endpoint, indicating a setback for the company's lead product candidate.
• The company has paused all drug development, including Adrulipase, in 2024 due to severe capital constraints, leading to a reduction in full-time employees from 15 to 2.
• The company is non-compliant with multiple Nasdaq listing requirements, including minimum stockholders' equity and minimum bid price, and faces potential delisting.
• A lawsuit for unpaid legal fees of $749,301.00 has been filed against the company by Ellenoff Grossman & Schole LLP.

Risks

• Our current dependency on external funding for our operations raises a substantial doubt about our ability to continue as a going concern, and failure to obtain necessary capital could force us to delay, limit, or terminate operations, or seek bankruptcy protection.
• If the transactions under the Rescission Agreement are not consummated, we will be liable for approximately $2,436,338 of ImmunogenX, LLC's secured debt and an additional approximately $46,000 of its accounts payable, potentially leading to further lawsuits and financial distress.
• Our failure to maintain compliance with Nasdaq's continued listing requirements, including minimum stockholders' equity, minimum bid price, and annual meeting requirements, could result in the delisting of shares of our Common Stock, adversely affecting liquidity and capital raising ability.
• Future sales of our common stock or the exercise of outstanding options and warrants could lower our stock price and dilute existing stockholders.
• We will require additional financing to advance the development of our lead product candidate, Adrulipase, which may not be available on acceptable terms, or at all, potentially forcing us to delay or terminate product development programs.
• Our management will have broad discretion over the use of the net proceeds from this offering, and these funds may be used for corporate purposes that do not increase our operating results or market value.
• There is no established public trading market for the Pre-funded Warrants being offered, and we do not intend to list them on any national securities exchange, limiting their liquidity.

Future Outlook

Entero Therapeutics plans to use the net proceeds from this offering to restart and advance its Adrulipase program, including hiring key personnel and preparing for future clinical milestones. The company anticipates needing additional capital to initiate a Phase 3 clinical trial for Adrulipase and plans to seek follow-on financing by the end of the third quarter of 2025 specifically for this purpose. They are also planning to initiate a Phase 2b clinical trial for Adrulipase in the second half of 2025. The company's ability to fund planned operations through March 2026 is contingent on successful financing efforts and the closing of the ImmunogenX rescission agreement.

Management Comments

• "We believe that the net proceeds of this offering, accounting for payments made to IR Agency LLC and together with our existing cash, will enable us to fund our operations for at least ten (10) months following the completion of this offering."
• "We believe that additional capital will be needed to begin a Phase 3 clinical trial for Adrulipase. In this regard, we plan to seek follow-on financing by the end of the third quarter of 2025, which will be used solely to fund the Phase 3 trials."
• "The Company expects that the closing of the Rescission Agreement will occur on or prior to June 30, 2025, subject to satisfaction of all conditions for closing, including obtaining shareholder approval by the Company for the transfer of the Membership Interests to the IMGX Shareholders."
• "The Companys decision to pursue a rescission agreement with ImmunogenX, LLC was driven by the strategic imperative to concentrate limited financial and operational resources on Adrulipase, the Companys primary drug candidate."
• "The Company believes this strategic refocusing is supported by multiple business and financial considerations: Elimination of Secured Debt Obligations, Resource Allocation Constraints, Historical Investment and Clinical Progress of Adrulipase, Market Opportunity for Adrulipase, Lack of Strategic Alignment with IMGX Product Lines, Streamlined Organizational Structure, Clearer Mission Purpose and Business Model."
• "While the Company is satisfied with the progress of the Adrulipase asset, it notes concerns with the efficacy of the Latiglutenase asset."
• "Given the material capital resources required to advance the IMGX Latiglutenase asset relative to the considerable risk of Phase 3 failure, the Company has determined that continued investment in IMGX is untenable and rescission is the best course of action."
• "Although the primary efficacy endpoint [for Adrulipase Phase 2b monotherapy] was not achieved, we believe that this may be on account of issues with quality control and clinical approach related to the study."

Industry Context

Entero Therapeutics operates in the highly capital-intensive biopharmaceutical sector, specifically targeting gastrointestinal diseases. The company's strategic shift to focus solely on Adrulipase for Exocrine Pancreatic Insufficiency (EPI) in cystic fibrosis and chronic pancreatitis patients reflects a common industry trend of narrowing focus to conserve capital and accelerate development of a lead asset, especially for smaller, cash-constrained companies. The decision to divest Latiglutenase, despite its potential, highlights the significant financial burden and high risk associated with advancing drug candidates through late-stage clinical trials (e.g., estimated $30 million for Latiglutenase Phase 3). The EPI market, currently dominated by porcine-derived PERTs with estimated sales of $2.1 billion in 2024 and a 20% CAGR, presents a substantial opportunity for a non-animal derived alternative like Adrulipase, if it can demonstrate superior efficacy and safety. The company's struggle with Nasdaq listing compliance is also a common challenge for small-cap biotech firms facing financial difficulties.

Comparison to Industry Standards

• The Adrulipase Phase 2b monotherapy trial's mean Coefficient of Fat Absorption (CFA) of 66% and 53% at different doses did not meet the targeted CFA of greater than or equal to 80%, which is generally considered indicative of adequate fat absorption in this patient population. This compares unfavorably to standard porcine pancreatic enzyme replacement therapy (PERT), which achieved mean CFAs of approximately 86% in previous comparator trials (e.g., Study AZ-CF2001).
• In contrast, the Adrulipase combination therapy with PERT achieved CFAs greater than 80% for all patients, demonstrating clinically meaningful improvements, with an average gain of more than six percentage points from baseline, exceeding the five-point improvement cited in clinical literature as clinically significant.
• The estimated $30 million required for Latiglutenase Phase 3 trials represents a significant capital investment, especially for a company with limited resources and no current revenue, highlighting the high cost of late-stage drug development in the biopharma industry.
• The PERT market, which Adrulipase aims to compete in, is well-established with estimated sales of approximately $2.1 billion in 2024 in the U.S. and a compound annual growth rate of approximately 20% over the past five years, indicating a robust and growing market.

Management Changes

Corporate Governance

Legal Proceedings

• **Mattress Liquidators, Inc. vs. ImmunogenX, LLC, Jack A. Syage, and The Jack A. Syage and Elizabeth T. Syage Revocable Trust**: A complaint was filed on December 31, 2024, for alleged breach of a credit agreement, seeking $7,575,568.91. The matter was settled on April 9, 2025, with Dr. Syage and his affiliated Trust agreeing to pay $5.5 million, and ImmunogenX, LLC paying $62,000 in legal fees. A new revolving loan of $2,436,338.30 was established for ImmunogenX, LLC, guaranteed by Dr. Syage and his Trust. The company will have no further liability if the rescission agreement closes.
• **Ellenoff Grossman & Schole LLP vs. Entero Therapeutics, Inc.**: A lawsuit was filed on March 17, 2025, seeking $749,301.00 for unpaid legal fees, costs, and disbursements from September 2023 through January 2025. The company is currently evaluating the claims and defenses, with a response deadline extended to June 30, 2025.

Related Party Transactions

• Dr. Jack Syage, a director and Chief Scientific Officer of the Company, is a former principal of ImmunogenX, LLC and a party to the settlement agreement with Mattress Liquidators, Inc., where he and his affiliated trust agreed to pay $5.5 million of ImmunogenX, LLC's debt and guarantee a new revolving loan.
• Dr. Syage and his affiliated entities will own approximately 42% of the transferred membership interests of ImmunogenX, LLC if the rescission agreement is consummated.
• The company issued 18,475 shares of Common Stock and 595.808 shares of Series G Preferred Stock to a consultant in connection with services relating to the ImmunogenX merger, which are not affected by the rescission agreement.

Stakeholder Impact

• **Shareholders**: Will experience immediate and substantial dilution from the offering. Existing shareholders face significant risk of further dilution from future capital raises and potential delisting from Nasdaq. The rescission of the ImmunogenX merger aims to protect shareholder value by reducing liabilities and focusing on the core asset.
• **Employees**: The company has drastically reduced its full-time employee headcount from 15 to 2 due to capital constraints, indicating job insecurity and potential impact on morale and operational capacity.
• **Creditors**: The company has significant outstanding liabilities and a history of non-payment (e.g., legal fees lawsuit). The planned capital raise and rescission agreement aim to address some liabilities, but the overall financial health remains precarious.
• **Customers/Patients**: The strategic focus on Adrulipase aims to bring a non-animal derived therapy to patients with EPI, potentially offering a new treatment option if successful. However, delays in drug development due to capital constraints could impact future patient access.
• **Suppliers**: The company's financial constraints and efforts to negotiate repayment of accounts payable (e.g., ImmunogenX's $695,000) could impact relationships with suppliers.

Next Steps

• Obtain shareholder approval for the ImmunogenX merger rescission agreement by June 30, 2025.
• Close the public offering of common stock and pre-funded warrants to raise approximately $4 million.
• Use proceeds to restart the Adrulipase program, including hiring a Chief Medical Officer (or Chief Scientific Officer) and covering associated operating expenses.
• Plan a Type C meeting with the FDA to discuss next steps for the Adrulipase program.
• Initiate a Phase 2b clinical trial for Adrulipase in the second half of 2025.
• Seek follow-on financing by the end of the third quarter of 2025 to fund Adrulipase Phase 3 trials.
• Evaluate claims and defenses for the lawsuit filed by Ellenoff Grossman & Schole LLP, with a response deadline extended to June 30, 2025.
• Monitor common stock bid price and consider options to regain Nasdaq compliance by September 1, 2025.
• Regain Nasdaq compliance for holding an annual meeting by June 30, 2025.
• Regain Nasdaq compliance for minimum stockholders' equity.

Key Dates

Recommendation

Keywords

Entero Therapeutics, Adrulipase, Exocrine Pancreatic Insufficiency, Cystic Fibrosis, Chronic Pancreatitis, Biopharmaceutical, SEC Filing, S-1/A, Capital Raise, Public Offering, ImmunogenX, Merger Rescission, Going Concern, Nasdaq Delisting, Clinical Trials, Drug Development, GI Diseases, Financial Distress, Biotech Investment